Molecularly Targeted Therapies in Non-Small-Cell Lung Cancer Annual Update 2014

被引：112

作者：

Morgensztern, Daniel ^{[1
]}

Campo, Meghan J. ^{[2
]}

Dahlberg, Suzanne E. ^{[3
]}

Doebele, Robert C. ^{[4
,5
]}

Garon, Edward ^{[6
]}

Gerber, David E. ^{[7
]}

Goldberg, Sarah B. ^{[8
,9
]}

Hammerman, Peter S. ^{[2
]}

Heist, Rebecca S. ^{[10
]}

Hensing, Thomas ^{[11
]}

Horn, Leora ^{[12
]}

Ramalingam, Suresh S. ^{[13
]}

Rudin, Charles M. ^{[14
]}

Salgia, Ravi ^{[11
]}

Sequist, Lecia V. ^{[10
]}

Shaw, Alice T. ^{[10
]}

Simon, George R. ^{[15
]}

Somaiah, Neeta ^{[15
]}

Spigel, David R. ^{[16
]}

Wrangle, John ^{[17
]}

Johnson, David ^{[18
]}

Herbst, Roy S. ^{[8
,9
]}

Bunn, Paul ^{[19
]}

Govindan, Ramaswamy ^{[1
]}

机构：

[1] Washington Univ, Sch Med, Dept Med Oncol, St Louis, MO 63110 USA

[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[3] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA

[4] Univ Colorado, Dept Med Oncol, Sch Med, Aurora, CO USA

[5] Univ Colorado, Ctr Canc, Aurora, CO USA

[6] UCLA Santa Monica Hematol Oncol, Santa Monica, CA USA

[7] Univ Texas SW Med Ctr Dallas, Harold C Simmons Canc Ctr, Div Hematol Oncol, Dallas, TX 75390 USA

[8] Yale Univ, Sch Med, Dept Med Oncol, New Haven, CT USA

[9] Ctr Canc, New Haven, CT USA

[10] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[11] Univ Chicago Med, Dept Oncol, Chicago, IL USA

[12] Vanderbilt Univ, Med Ctr, Div Hematol Oncol, Nashville, TN USA

[13] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA

[14] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[15] Med Univ S Carolina, Dept Hematol Oncol, Charleston, SC 29425 USA

[16] Sarah Cannon Res Inst, Nashville, TN USA

[17] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA

[18] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA

[19] Univ Colorado, Sch Med, Div Med Oncol, Denver, CO USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 01期

关键词：

Non-small-cell lung cancer; Targeted therapies; Immunotherapy; RECEPTOR TYROSINE KINASE; PHASE-II TRIAL; FIBROBLAST GROWTH-FACTORS; ETV6-NTRK3 GENE FUSION; DNA-DAMAGING AGENTS; C-MET ANTIBODY; ACQUIRED-RESISTANCE; EGFR-MUTANT; 1ST-LINE TREATMENT; OPEN-LABEL;

D O I：

10.1097/JTO.0000000000000405

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

There have been significant advances in the understanding of the biology and treatment of non-small-cell lung cancer (NSCLC) during the past few years. A number of molecularly targeted agents are in the clinic or in development for patients with advanced NSCLC. We are beginning to understand the mechanisms of acquired resistance after exposure to tyrosine kinase inhibitors in patients with oncogene addicted NSCLC. The advent of next-generation sequencing has enabled to study comprehensively genomic alterations in lung cancer. Finally, early results from immune checkpoint inhibitors are very encouraging. This review summarizes recent advances in the area of cancer genomics, targeted therapies, and immunotherapy.

引用

页码：S1 / S63

页数：63

共 328 条

[11]

[Anonymous], ASCO ANN M P

[12]

[Anonymous], 2014, J CLIN ONCOL S

[13]

[Anonymous], 2011, J CLIN ONCOL

[14]

[Anonymous], 2014, J CLIN ONCOL S

[15]

[Anonymous], 2013, ASCO M

[16]

Appleman LJ, 2012, J CLIN ONCOL, V30

[17] Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas [J].

Arcila, Maria E. ;

Chaft, Jamie E. ;

Nafa, Khedoudja ;

Roy-Chowdhuri, Sinchita ;

Lau, Christopher ;

Zaidinski, Michael ;

Paik, Paul K. ;

Zakowski, Maureen F. ;

Kris, Mark G. ;

Ladanyi, Marc .

CLINICAL CANCER RESEARCH, 2012, 18 (18) :4910-4918

[18] A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations [J].

Asahina, H. ;

Yamazaki, K. ;

Kinoshita, I. ;

Sukoh, N. ;

Harada, M. ;

Yokouchi, H. ;

Ishida, T. ;

Ogura, S. ;

Kojima, T. ;

Okamoto, Y. ;

Fujita, Y. ;

Dosaka-Akita, H. ;

Isobe, H. ;

Nishimura, M. .

BRITISH JOURNAL OF CANCER, 2006, 95 (08) :998-1004

[19]

Awad MM, 2013, NEW ENGL J MED, V369, P1173, DOI [10.1056/NEJMc1309091, 10.1056/NEJMoa1215530]

[20] The future of epigenetic therapy in solid tumours-lessons from the past [J].

Azad, Nilofer ;

Zahnow, Cynthia A. ;

Rudin, Charles M. ;

Baylin, Stephen B. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2013, 10 (05) :256-266

← 1 2 3 4 5 6 7 8 9 10 →